Fernad Delorme, MD

Articles by Fernad Delorme, MD

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,Michael Smylie, MD,John R. Mackey, MD,Dick Au, MD,Evelyn Sansregret, MD,Daniel Noel, MD,Alexander H. Paterson, MD,Taher Al-tweigeri, MD,Fernad Delorme, MD,Allesandro Riva, MD

August 1st 1997

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for

Latest Updated Articles

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer
August 1st 1997

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)